An interventional study of The AquaPass System in Acute Kidney Failure and Chronic Kidney Diseases, sponsored by AquaPass Medical Ltd.. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.
Sponsored by AquaPass Medical Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Acute Kidney Injury with a site in Israel — 3 open to participants now, 4 under way, none of them phase 3. Acute Kidney Injury · Israel.
Among the 13 studies in Acute Kidney Injury with a site in Israel, this one is the only one that started in 2023, is one of 4 with no phase, and was the 10th registered.
1,692 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →3 of the 13 studies in Acute Kidney Injury with a site in Israel are open now. Recruiting first, the newest first:
FIZE Medical ltd · Sites in Israel
Ages 18+
Indiana University · Sites in Israel, United States, Argentina and 30 more countries
Ages 0 min–2 wk
Meir Medical Center · Sites in Israel
Ages 18–100
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 30 across the 7 interventional studies, 250 across the 6 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 10 most frequent:
AquaPass Medical Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
AquaPass Medical Ltd. has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
2 of the studies in Acute Kidney Injury with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07022314FIZE Medical ltdUrine Output Response to Fluid and Diuretic Therapy in Cardiac ICU Patients Monitored With FIZE kUO® | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Acute Kidney Injury with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To demonstrate safety and performance of AquaPass System for improving fluid balance in hemo-dialysis patients, by increasing fluid loss via the skin.
This study requires several investigational tests, exams, and data collection procedures to be performed by the participants. These procedures are listed in abbreviated format in the Schedule of Assessments/Activities table. The final eligibility of the trial will be confirmed after a 2-hour acclimatization session. The trial-specific procedures must not be performed until the participant has signed a written informed consent form, which has been approved by the site's Institutional Review Board.
The investigator or designee, who is trained in the clinical investigation plan, will explain the nature and scope of the trial to the participant. They will also discuss the potential risks and benefits of participation and answer any questions the participant may have. If the participant agrees to participate, they must sign the informed consent form. The investigator/designee must also sign the form before the participant can be enrolled in the trial. Any additional persons required by the site's Institutional Review Board to sign the informed consent form must also comply.
Each participant's study duration will be approximately 8 weeks. The study duration will be identical for all participants, as follows:
Screening Period: This period will last up to 7 days, during which time the participant's eligibility for the trial will be determined.
Observation Period: This period will last 3 weeks, during which the participant will come to the medical study center for weekly assessments.
Procedure Period: This period will last 4 weeks, during which time the participant will undergo 2-3 procedures with the AquaPass device each week. These procedures will be in addition to their regular hemodialysis treatment. The participant will undergo 2 procedures during the weekend, and each procedure will last 3-8 hours.
Follow-Up: This period will last 7(±1) days from the last procedure. During this period, the participant's health status will be monitored.
In summary, the study requires participants to undergo several investigational tests, exams, and data collection procedures. The study duration for each participant will be approximately 8 weeks, during which time they will undergo a screening period, observation period, procedure period, and follow-up period. All participants must provide written informed consent before any trial-specific procedures can be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This study will be a crossover study with one center and an open label design. Patients who sign the informed consent form and meet the inclusion and exclusion criteria will undergo a 2-hour acclimatization period to verify their ability to adhere to the AquaPass procedure. Once enrolled, patients will undergo a 3-week observation period where they will continue with their regular hemodialysis treatment with no changes. Study endpoint parameters will be assessed during this observation period and used as a control group. After the observation period, patients will undergo the AquaPass procedure 2-3 times a week for 4 weeks. Study assessments will be conducted at the beginning of each week during the patient's dialysis session.
Device: The AquaPass System
The system is a non-invasive, renal-independent, single-patient, multiple-use device intended for use at the hospital, outpatient clinic, or home. The system administers warm, dry air around the patient's body to create an environmental condition that activates the eccrine glands to produce sweat, in return it removes fluids from the interstitial compartment, where fluids accumulate in fluid overload.
Differences in weight gain over the long interdialytic period
weight at the end of the last Hemodialysis session before AquaPass therapy subtracted from the weight in the morning of the first Hemodialysis session of the week after AquaPass therapy.
Time frame: Up to 50 days
Device related Adverse Events
Safety evaluation of device-related adverse effects
Time frame: Up to 60 Days
Changes in NT-proBNP
Changes in biomarkers of congestion
Time frame: Up to 50 days
Changes in Blood Urea Nitrogen
Changes in Blood Urea Nitrogen levels
Time frame: Up to 50 days
Effect on Quality of Life
change in the quality of life measured by the Kansas City Cardiomyopathy Questionnaire. In this questionnaire the minimum score is '0' and the maximum is '100', and higher scores represent a better outcome for the patient.
Time frame: up to 50 days
Affect on Ultrafiltration Rates after the long inter dialytic gap
Evaluation of the changes in ultrafiltration rates between the control phase and the Aquapass phase in the first dialysis session after the long interdialytic period
Time frame: up to 28 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Nov 2023, 7 months.
Of 269 interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AquaPass Medical Ltd.